ChemotherapyPhase 3 trialInvestigational
Platinum-based chemotherapy (e.g. Carboplatin)
Generic name: carboplatin
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Efficacy
Studies are ongoing to evaluate the efficacy of platinum-based chemotherapy in patients with advanced prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | meta-analysis | — | Source → |
| Testing a New Treatment for Brain Metastases from Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Ivonescimab with Chemotherapy in Early-Stage Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | observational | Five-year overall survival and recurrence-free survival numerically favored cisplatin (61.0% vs 48.8%, P=0.17; 63.9% vs 56.6%, P=0.12). | Source → |
| Testing a New Treatment Combination for Unresectable Pleural Mesothelioma | Lung Cancer | phase-3 | — | Source → |
| Comparing Carboplatin and Cisplatin in Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| Testing a Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Cancer Researchers Study Re-Challenging a Patient with Platinum-Based Chemotherapy | Lung Cancer | observational | — | Source → |
| Testing HIFU and PD-1 Inhibitors in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing SKB500 Combinations in Small Cell Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Carboplatin in Triple-Negative Breast Cancer Treatment | Breast Cancer | observational | The pCR rate was significantly higher in the platinum group than in the non-platinum group (68.9% vs. 50.5%). | Source → |
| Ovarian Cancer Treatment Trial Evaluates IMNN-001 Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Combination Therapy for Extensive-stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating a New Treatment for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Hereditary Breast-Ovarian Cancer Syndrome Responds to Chemotherapy | Ovarian Cancer | observational | The patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. | Source → |
| Targeted Cancer Treatment Shows Promise in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| New Lung Cancer Treatment Shows Promise in Early Study | Lung Cancer | phase-3 | The median overall survival was 10.7 months, and the median progression-free survival was 5.5 months. | Source → |
| Comparing Two Ways to Give Carboplatin for Triple-Negative Breast Cancer | Breast Cancer | observational | pCR rates were 50% with weekly and 61% with tri-weekly regimens. | Source → |
| New Cancer Treatment Uses Heat to Release Medicine | Ovarian Cancer | lab-study | — | Source → |
| Nafamostat Mesylate Sensitizes Ovarian Cancer Cells to Carboplatin | Ovarian Cancer | lab-study | — | Source → |
| BDNF's Role in Colon Cancer's Resistance to Carboplatin | Colorectal Cancer | lab-study | — | Source → |
| Carboplatin Resistance in Ovarian Cancer Linked to β-Tubulin Changes | Ovarian Cancer | lab-study | — | Source → |
| Carboplatin dosing in ovarian cancer treatment: A study on renal function estimation | Ovarian Cancer | phase-3 | — | Source → |
| New Options for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The risk of death was significantly decreased with carboplatin + pegylated liposomal doxorubicin + bevacizumab compared to platinum-based doublet CT (hazard ratio [HR] = 0.59, 95%CI 0.35, 1). | Source → |
| New Compound Enhances Chemotherapy Effectiveness in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Chemotherapy Agent Enhances Tumor-Fighting Cells | Ovarian Cancer | animal-study | — | Source → |
| Combining Avelumab and Carboplatin in Advanced Prostate Cancer | Prostate Cancer | preclinical | The objective response rate was 17.6%, including one complete response (5.9%). | Source → |
| Carboplatin Dose Calculations for Lung Cancer Patients Vary Depending on Dosing Equation | Lung Cancer | observational | — | Source → |
| Understanding how ovarian cancer becomes resistant to carboplatin | Ovarian Cancer | lab-study | — | Source → |
| Anaphylactic Reaction to Carboplatin Diagnosed by Skin Testing | Ovarian Cancer | observational | — | Source → |
| Combining birinapant and carboplatin may help target ovarian cancer cells | Ovarian Cancer | lab-study | — | Source → |
| Weekly vs. Tri-Weekly Paclitaxel for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | There was likely a slight improvement in progression-free survival when paclitaxel was dosed weekly compared to tri-weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98). | Source → |
| Desensitization Therapy for Carboplatin Side Effects | Ovarian Cancer | observational | — | Source → |
| Adding carboplatin to breast cancer treatment may improve long-term outcomes | Breast Cancer | phase-3 | The hazard ratio for event-free survival was 0.63 (95% CI 0.43-0.92, P = 0.02) for carboplatin plus veliparib with paclitaxel versus paclitaxel. | Source → |
| Researchers Investigate Chemotherapy for Rare Lung Cancer | Leukemia | phase-2 | The overall response rate was 25.0% and disease control rate was 56.3%. | Source → |
| Combining Azacitidine and Carboplatin May Help Boost Immune Response in Ovarian Cancer | Ovarian Cancer | lab-study | Sequential azacitidine and carboplatin significantly slowed cell growth in 50% of cell lines compared to carboplatin alone. | Source → |
| Risk Factors for Carboplatin Allergic Reactions in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Ovarian Cancer Survival Rates in Northern India | Ovarian Cancer | observational | The median recurrence-free survival was 30 (95% confidence interval: 24.65-35.38) months. | Source → |
| Comparing Chemotherapy Treatments for Esophageal Cancer | Lung Cancer | phase-2 | The overall response rate in the taxane-based group was higher than the non-taxane-based group, but was not significantly different (p=0.851). | Source → |
| Chemotherapy May Cause Ovarian Cancer Cells to Become Dormant | Ovarian Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | phase-2 | 61.4% of patients in the DCb group achieved a pathologic complete response. | Source → |
| Ovarian Cancer Treatment Study Finds Key Prognostic Factors | Ovarian Cancer | preclinical | Median progression-free survival was 20.8 months, and median overall survival was 41.1 months. | Source → |
| Rare Pancreatic Cancer Responds to New Chemotherapy Combination | Pancreatic Cancer | phase-2 | — | Source → |
| Chemotherapy Affects Heart Function in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Low-dose chemotherapy may enhance lung cancer treatment | Lung Cancer | lab-study | — | Source → |
| Lab Tests Show Different Results for Cancer Drug in 3D Models | Ovarian Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.